top of page

USFDA's Notice: CMC Development & Readiness Pilot Program

Recently in a new program announced by the Food and Drug Administration (USFDA), a limited number of applicants will be able to participate in a Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP) program.

Development programs for CBER- and CDER-regulated drugs and biologics intended to diagnose, treat, or prevent a serious disease or condition where there is an unmet medical need may have accelerated clinical development timelines.


FDA will accept applications for participation in the CDRP program starting April 1, 2023, and will select no more than nine proposals, approximately two-thirds of which will be CBER-regulated products and one-third will be CDER-regulated products.


The purpose of this program is to expedite the development of products under investigational new drug (IND) applications, where warranted, based on the likelihood that patients will benefit from earlier access to these products.


Sponsors participating in the pilot program will receive product-specific CMC advice from FDA during product development, including two additional CMC-focused Type B meetings, as well as a limited number of additional CMC-focused discussions based on readiness and defined milestones.


The CDRP will increase the communication between FDA and the sponsors to ensure that adherence to CMC requirements for marketing applications is understood mutually.


Comments


I Sometimes Send Newsletters

Thanks for submitting!

  • LinkedIn
  • Facebook
  • Twitter
  • Instagram

DISCLAIMER

The views expressed in this publication do not necessarily reflect the views of any guidance of government, health authority, it's purely my understanding. This Blog/Web Site is made available by a regulatory professional, is for educational purposes only as well as to give you general information and a general understanding of the pharmaceutical regulations, and not to provide specific regulatory advice. By using this blog site you understand that there is no client relationship between you and the Blog/Web Site publisher. The Blog/Web Site should not be used as a substitute for competent pharma regulatory advice and you should discuss from an authenticated regulatory professional in your state.  We have made every reasonable effort to present accurate information on our website; however, we are not responsible for any of the results you experience while visiting our website and request to use official websites.

bottom of page